Prescription medicine
Olodaterol Brand names: Striverdi; first approved as Striverdi Respimat
Olodaterol (Striverdi) is a prescription medicine with an FDA approval on record since 2014. No generic is listed; pharmacies paid $65.94 per gram (Striverdi respimat inhal spray) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the olodaterol FDA label on DailyMed (effective January 3, 2025, Boehringer Ingelheim Pharmaceuticals, Inc.); the NDA 203108 record on Drugs@FDA; every olodaterol label on DailyMed.
Highlights of the record
FDA label of January 3, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSTRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Forms and strengths
Spray (metered).
On the market
- Earliest approval on file
- July 31, 2014 Striverdi Respimat, Boehringer Ingelheim; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- January 19, 2027 Striverdi Respimat spray; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $65.94 per gram Striverdi respimat inhal spray
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 370 through July 30, 2026
What is olodaterol used for?
From the label: indications and usageSTRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. […]
Conditions named in the indications of olodaterol's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: beta2-Adrenergic Agonist.
Source: FDA drug label (Striverdi Respimat), Boehringer Ingelheim Pharmaceuticals, Inc., effective January 3, 2025 (SPL set 5d9a5433-857e-44ea-b3d6-2a400ca0cef5), via openFDA; the full label on DailyMed
Is there a generic for olodaterol (Striverdi)?
No generic olodaterol is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Striverdi Respimat spray: the compound patent runs to January 19, 2027. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2014 earliest approval on file
- 2027 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for olodaterol (Striverdi)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $65.94 per gram (Striverdi respimat inhal spray), up 3% from $64.05 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Striverdi respimat inhal spray (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Striverdi respimat inhal spray | Brand | $65.94 per gram | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the olodaterol label say about other medicines?
The olodaterol label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | warnings and precautions | Doses of the related beta 2 -agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis. |
| Ketoconazole | drug interactions | In a drug interaction study using the strong dual CYP and P-gp inhibitor ketoconazole, a 1.7-fold increase of maximum plasma concentrations and AUC was observed [see Clinical Pharmacology (12.3) ]. |
| Salmeterol | warnings and precautions | A 28-week, placebo-controlled US study comparing the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; |
Source: FDA drug label (Striverdi Respimat), Boehringer Ingelheim Pharmaceuticals, Inc., effective January 3, 2025 (SPL set 5d9a5433-857e-44ea-b3d6-2a400ca0cef5), via openFDA; the full label on DailyMed
What do FAERS reports show for olodaterol?
The FDA Adverse Event Reporting System holds 370 reports that list olodaterol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 19 are coded as a death and 95 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as olodaterol?
16 other medicines are given the same way (respiratory (inhalation)) and in the same FDA class as olodaterol or labeled mainly for the same use (COPD), the same class first. COPD lists all 23 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (respiratory (inhalation)) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Fluticasone and salmeterol | COPD | 8 labelers | $1.07 per unit 100-50 | A presentation being discontinued |
| Albuterol and ipratropium | COPD | 14 labelers | $0.0787 per mL 0.5-3(2.5) mg/3 mL | No current entry |
| Budesonide and formoterol | COPD | 2 labelers | $17.26 per gram 160-4.5 | No current entry |
| Arformoterol | COPD | 15 labelers | $0.633 per mL 15 mcg/2 mL solution | No current entry |
| Formoterol | COPD | 11 labelers | $1.30 per mL 20 mcg/2 mL neb vial | No current entry |
| Fluticasone and vilanterol | COPD | none listed | $3.90 per unit 100-25 | No current entry |
| Budesonide and formoterol and glycopyrrolate | COPD | none listed | $61.41 per gram 160-9-4.8 mcg | No current entry |
| Fluticasone and umeclidinium and vilanterol | COPD | none listed | $11.12 per unit 100-62.5-25 | No current entry |
Every medicine labeled for the same conditions as olodaterol
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does olodaterol compare with medicines for the same use?
1 side-by-side page set olodaterol beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to olodaterol
- 16 medicines for the same use
- Other beta-2 agonists
- the pharmacologic class, with prices and generics
- Olodaterol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other